Friday, September 4, 2015

Hydra Biosciences to have Phase 1 TRPA1 data soon

Hydra Biosciences to have Phase 1 TRPA1 data soon

September 1, 2015 by · Leave a Comment 

Tweet Closely-held Hydra Biosciences expects to complete Phase 1 trials of its HX-100 inhibitor of the Transient Receptor Potential (TRPA1) ion channel as a treatment for painful diabetic neuropathy and allergic asthma by the end of this year. “We expect to file regulatory documents by the end of December to initiate Phase 2 trials in […]

Peritech readies U.S. launch of novel hemorrhoid gel

Peritech readies U.S. launch of novel hemorrhoid gel

August 24, 2015 by · Leave a Comment 

Tweet Closely-held Peritech Pharma of Israel is in discussions with potential marketing partners for a U.S. launch of its once-daily over-the-counter gel, now known as PP-110, for the treatment of hemorrhoids. “PP-110 contains the same active pharmaceutical ingredients as Pfizer’s Preparation-H cream: pramoxine-HCI 1% and phenylephrine-HCI 0.25%,” Raveh Gill-More, VP of business development, says in […]

Cellectar Biosciences refocusing on therapeutics

Cellectar Biosciences refocusing on therapeutics

August 18, 2015 by · Leave a Comment 

Tweet After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Cellectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and cancer-targeting delivery of oncologic payloads. “We were previously focused on advancing our diagnostic assets, with no plan to take advantage of our cancer therapeutics beyond […]

BriaCell readies trial of breast cancer vaccine

BriaCell readies trial of breast cancer vaccine

August 11, 2015 by · Leave a Comment 

Tweet BriaCell Therapeutics (OTCQX:ANCCF; TSX-V:BCT) anticipates enrolling the first patient later this year in a Phase 1/2 open label study of its BriaVax vaccine in up to 24 breast cancer patients with advanced stages of solid tumors. “While the current focus of the company remains late-staged breast cancers, we recognized that the technology may have […]

In conversation with Nicole Grannell

In conversation with Nicole Grannell

August 4, 2015 by · Leave a Comment 

Tweet As vice-president of business development for Bay Area Research Logistics (BARL), a specialized clinical trial design, packaging and logistics firm, Nicole Grannell manages the logistical components of multinational clinical trials, both in developed and emerging markets. Ms. Grannell began her sales and marketing career with Big Pharma in Canada, specifically Wyeth and Boehringer Ingelheim. […]

Matinas BioPharma moves focus to anti-infectives

Matinas BioPharma moves focus to anti-infectives

July 28, 2015 by · Leave a Comment 

Tweet After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. “Our initial focus is to take powerful, but sparingly used, anti-fungal and anti-bacterial drugs and increase their safety and potency,” president and CEO, Roelof Rongen, […]

Xenon still committed to TV-45070 for neuropathic pain

Xenon still committed to TV-45070 for neuropathic pain

July 21, 2015 by · Leave a Comment 

Tweet Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for neuropathic pain indications, even though it failed a Phase 2b study in pain due to osteoarthritis (OA) of the knee. “We and Teva believe that the reason the topical ointment did […]

In conversation with Heather Morehouse Ettinger

In conversation with Heather Morehouse Ettinger

July 14, 2015 by · Leave a Comment 

Tweet As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and patent counseling and procurement in the biotechnology and pharmaceutical fields. She regularly handles domestic and international patent portfolios, and due diligence studies for clients, including […]

M Pharma advancing technologies for obesity and diabetes

M Pharma advancing technologies for obesity and diabetes

July 7, 2015 by · Leave a Comment 

Tweet M Pharmaceutical (OTCQB:MPHMF; CSE:MQ; FWB:T3F1.F) is advancing a family of biomedical technologies to manage obesity – TriMeo and TriMtec – and eMosquito to manage diabetes. “All three of our technologies represent a spectrum of solutions with reduced invasiveness and enhanced effectiveness than currently available approved solutions,” Dr. Martin Mintchev, president and CEO, says in […]

Regenicin readying clinical trials of NovaDerm skin substitute

Regenicin readying clinical trials of NovaDerm skin substitute

June 30, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=o1ewAheYSXs’]

Tweet Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of 2015 as well as file for worldwide designation of NovaDerm as an orphan product. “We expect to be in […]

Next Page »

Email Newsletters with Constant Contact
Google+